Anja Winter

Dr. Anja Winter

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
HJHarry Jubb
Harry Jubb
AHAlicia P. Higueruelo
Alicia P. Higueruelo
AWAnja Winter
Anja Winter
TBTom L. Blundell
Tom L. Blundell

13 September 2012 in Quarterly Reviews of Biophysics
Verified
Journal Article
Closed access
AWAnja Winter
Anja Winter
AHAlicia P. Higueruelo
Alicia P. Higueruelo
MMMay Marsh
May Marsh
ASAnna Sigurdardottir
Anna Sigurdardottir
WPWill R Pitt
Will R Pitt
TBTom L. Blundell
Tom L. Blundell
Drug discovery has classically targeted the active sites of enzymes or ligand-binding sites of receptors and ion channels. In an attempt to improve selectivity of drug candidates, modulation of protein–protein interfaces (PPIs) of multiprotein complexes that mediate conformation or colocation of components of cell-regulatory pathways has become a focus of interest. However, PPIs in multiprotein systems continue to pose significant challenges, as they are generally large, flat and poor in distinguishing features, making the design of small molecule antagonists a difficult task. Nevertheless, encouragement has come from the recognition that a few amino acids – so-called hotspots – may contribute the majority of interaction-free energy. The challenges posed by protein–protein interactions have led to a wellspring of creative approaches, including proteomimetics, stapled α-helical peptides and a plethora of antibody inspired molecular designs. Here, we review a more generic approach: fragment-based drug discovery. Fragments allow novel areas of chemical space to be explored more efficiently, but the initial hits have low affinity. This means that they will not normally disrupt PPIs, unless they are tethered, an approach that has been pioneered by Wells and co-workers. An alternative fragment-based approach is to stabilise the uncomplexed components of the multiprotein system in solution and employ conventional fragment-based screening. Here, we describe the current knowledge of the structures and properties of protein–protein interactions and the small molecules that can modulate them. We then describe the use of sensitive biophysical methods – nuclear magnetic resonance, X-ray crystallography, surface plasmon resonance, differential scanning fluorimetry or isothermal calorimetry – to screen and validate fragment binding. Fragment hits can subsequently be evolved into larger molecules with higher affinity and potency. These may provide new leads for drug candidates that target protein–protein interactions and have therapeutic value.

30 October 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
PMPatrick J. McIntyre
Patrick J. McIntyre
PCPatrick Collins
Patrick Collins
LVLukáš Vrzal
Lukáš Vrzal
KBKristian Birchall
Kristian Birchall
LALaurence H. Arnold
Laurence H. Arnold
RBRichard Bayliss
Richard Bayliss

10 April 2007 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
AWAnja Winter
Anja Winter
OKOuti Kämäräinen
Outi Kämäräinen
AHAndreas Hofmann
Andreas Hofmann

16 November 2005 in Biochemistry
Verified
Journal Article
Closed access
NDNicole Dabitz
Nicole Dabitz
Nien-Jen HuNien-Jen Hu
Nien-Jen Hu
AYAdlina Mohd Yusof
Adlina Mohd Yusof
NTNicola Tranter
Nicola Tranter
AWAnja Winter
Anja Winter
AHAndreas Hofmann
Andreas Hofmann

1 May 2012 in Biotechnology Advances
Verified
Journal Article
Closed access
AOAsiah Osman
Asiah Osman
CWConan Wang
Conan Wang
AWAnja Winter
Anja Winter
Alex LoukasAlex Loukas
Alex Loukas
LTLeon Tribolet
Leon Tribolet
AHAndreas Hofmann
Andreas Hofmann